Johnson P R, Feldman S, Thompson J M, Mahoney J D, Wright P F
J Infect Dis. 1986 Jul;154(1):121-7. doi: 10.1093/infdis/154.1.121.
Live attenuated, cold-adapted (ca) influenza A vaccines administered intranasally have been well characterized as safe and immunogenic, but comparative data on protective efficacy are required for further development. In this study, 59 young children were divided into the following four groups based on prior exposure to influenza A (H3N2) virus: natural infection, live ca vaccine given intranasally, inactivated vaccine given im, and no previous exposure. Virus challenge with homologous live ca vaccine occurred 12 months after vaccination or natural infection. Prior natural infection and live ca vaccine significantly reduced ca virus shedding after challenge compared with inactivated vaccine or no prior exposure to influenza A virus. Prechallenge nasal IgA, detected almost exclusively in subjects naturally infected or vaccinated with live ca virus, was associated with protection. Although inactivated vaccine failed to produce significant local IgA during the primary response, it seemed to prime for secondary local antibody responses after challenge with live ca virus.
经鼻内接种的减毒活、冷适应(ca)甲型流感疫苗已被充分证明是安全且具有免疫原性的,但进一步研发需要关于保护效力的比较数据。在本研究中,59名幼儿根据既往甲型(H3N2)流感病毒暴露情况被分为以下四组:自然感染、经鼻内接种减毒活疫苗、肌肉注射灭活疫苗以及无既往暴露史。在接种疫苗或自然感染12个月后,用同源减毒活疫苗进行病毒攻击。与灭活疫苗或无甲型流感病毒既往暴露史相比,既往自然感染和减毒活疫苗在攻击后显著减少了ca病毒排出。攻击前的鼻腔IgA几乎仅在自然感染或接种减毒活病毒的受试者中检测到,与保护作用相关。虽然灭活疫苗在初次反应期间未能产生显著的局部IgA,但在用减毒活病毒攻击后,它似乎能引发二次局部抗体反应。